Baird's Investment Banking Group is pleased to announce the following transaction:

Date:
July 2021
Company:
Premier Research Group
Description:
Acquisition of Camargo Pharmaceutical Services
Sector(s):
Healthcare
Baird served as the exclusive financial advisor to Premier Research Group on this transaction

Premier Research Group (“Premier Research” or the “Company”), a portfolio company of Metalmark Capital, recently acquired Camargo Pharmaceutical Services ("Camargo").

Premier Research, a clinical research and development company, is dedicated to helping biotech, specialty pharma, and device innovators transform life-changing ideas and breakthrough science into new medical treatments. As a global company, Premier Research specializes in the use of innovative technologies for smart study design and trial management to deliver clean, conclusive data to sponsors. Whether it's developing product lifecycle strategies, reducing clinical development cycle times, securing access to patients, navigating global regulations, maximizing the impact of limited rare disease data, or providing expertise in specific therapeutic areas, Premier Research is committed to helping its customers answer the unmet needs of patients across a broad range of medical condition. The Company is headquartered in Morrisville, North Carolina.

Metalmark Capital is a leading private equity firm that seeks to build long-term value through active and collaborative partnerships with business owners, founders and executives. Metalmark Capital focuses its investment activity in healthcare, industrials & infrastructure and agribusiness. Metalmark Capital manages funds with $3.7 billion in aggregate capital commitments.

Camargo Pharmaceutical Services is a leading global strategy, regulatory and commercial partner for emerging biopharma companies. Camargo specializes in rare and complex development programs where no playbook exists, with integrated solutions to reach milestones with speed and capital efficiency. Camargo has experience in complex development programs and accelerated approval pathways that leverage core expertise in areas such as oncology, pediatrics, rare disease, and 505(b)(2). Camargo supports clients in more than 35 countries around the world. Camargo is headquartered in Cincinnati, Ohio.

For additional information about this transaction, please contact:

Adam Huitt +1-704-553-6623
Jeff Seaman +1-312-609-4687
Miguel Mireles +1-414-298-2478
Andrew Nicholson +44-20-7667-8509